Search Results
Your search for The ASCO matches 21410 pages
Showing 12851 - 12900Liquid Biopsies Identify Distinct Genomic Profiles With Potentially Targetable Alterations in Carcinoma of Unknown Primary
Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7% of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published by Kato et al in Cancer Research....
Detection of Early-Stage Cancers With Circulating Tumor DNA
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...
Off-the-Shelf, Virus-Specific T Cells for Treating Viral Infections After Transplantation
In a phase II study reported in the Journal of Clinical Oncology, Tzannou et al found that use of off-the-shelf, broad-coverage, adoptively transferred, virus-specific T cells was feasible and effective in treating viral infections in patients who had undergone allogeneic hematopoietic stem cell...
Carlos L. Arteaga, MD, Named Director of UT Southwestern Cancer Center
CARLOS L. ARTEAGA, MD, has been named Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at The UT Southwestern Medical Center in Dallas. Roles and Research at Vanderbilt DR. ARTEAGA IS CURRENTLY Director of the Center for Cancer Targeted...
Patricia Ganz, MD, Appointed Editor-in-Chief of JNCI
ON JULY 1, Patricia Ganz, MD, assumed editorial leadership of JNCI: Journal of the National Cancer Institute. As Editor-in-Chief, she is also responsible for JNCI Monographs. Dr. Ganz is Director of Cancer Prevention & Control Research at the University of California Los Angeles (UCLA)’s...
Brachytherapy for Prostate Cancer: An Old Form of Radiation Treatment That Is Still One of the Most Effective
BRACHYTHERAPY HAS a long track record in treating cancer, dating back to the first reported use of an implanted radioactive source in 1901, and brachytherapy for the treatment of prostate cancer dates back to 1914, when Pasteu and Degrais used a radium source inserted through a urethral catheter. ...
ASCO/Cancer Care Ontario Joint Guideline Update: Brachytherapy for Patients With Prostate Cancer
AS REPORTED by Joseph Chin, MD, of London Health Sciences Centre, London, Ontario, and colleagues in the Journal of Clinical Oncology, ASCO and Clinical Care Ontario (CCO) have issued a joint update to the prior CCO guideline on use of brachytherapy in patients with prostate cancer.1,2 The update ...
Team Aims to Apply CAR T-Cell Therapy to Pancreatic Cancer
STAND UP TO CANCER (SU2C) and Lustgarten Foundation for Pancreatic Cancer Research are supporting a new translational research team to explore how chimeric antigen receptor (CAR) T-cell therapy can be applied to pancreatic cancer. The approach uses specially modified immune cells to find and...
Pursuing Combination Strategies With Checkpoint and Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma
PRIMARY LIVER CANCER is the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma accounts for 90% of liver cancer, with around 800,000 new cases diagnosed globally each year.1 In contrast to the stable or declining trends observed for most neoplasms, the incidence and...
New ASCO Recommendations for Controlling Nausea and Vomiting Related to Cancer Treatment
AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology,1 provides new evidence-based information on the appropriate use of olanzapine, neurokinin 1 (NK1)...
International Consensus (or Not) on Management of Advanced Prostate Cancer
ALTHOUGH THE National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) strongly influence the management of advanced prostate cancer, they do not always reflect actual clinical practice. It turns out that in the real world, there are multiple areas ...
First Universal Childhood Cancer Data Lab Opens
ALEX’S LEMONADE STAND FOUNDATION (ALSF) has announced the opening of the first-of-its-kind Childhood Cancer Data Lab (CCDL) with the mission of accelerating cures. ALSF first announced the CCDL at the National Cancer Moonshot Summit in Washington, DC, hosted by former Vice President Joe Biden and...
Cutting-Edge Induction Strategies and Novel Approach to Reducing Skeletal-Related Events Explored in Multiple Myeloma
THE ADDITION of daratumumab (Darzalex) to a triplet induction regimen led to good responses in newly diagnosed multiple myeloma, but not without toxicities. And in the treatment of myeloma bone disease, denosumab (Xgeva) in place of zoledronic acid preserved renal function and may be associated...
Updates of Key Trials in Metastatic Non–Small Cell Lung Cancer: KEYNOTE-024 and AvaALL
IMMUNOTHERAPY AND ANTIANGIOGENESIS were highlighted in a session on metastatic non–small cell lung cancer (NSCLC) at the Best of ASCO New Orleans meeting. Matthew Gubens, MD, MS, presented the selected abstracts from the ASCO Annual Meeting.1 Dr. Gubens is Associate Professor of Thoracic Medical...
Fighting Misinformation in HPV-Related Cancer Prevention
FAKE NEWS, junk science, and alternative facts seem pervasive in our current culture, to the detriment of important, verified scientific advancements. One area where this is quite evident is the vaccine against human papillomavirus (HPV). Although we have had a safe, effective vaccine since 2006...
FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer
On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to...
FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-Cell Precursor ALL
On August 17, 2017, the U.S. Food and Drug Administration (FDA) approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). INO-VATE ALL The approval was based on data from INO-VATE ALL, a randomized (1:1), ...
Reuben Shaw, PhD, Receives NCI Outstanding Investigator Award
Salk Institute for Biological Studies Professor Reuben Shaw, PhD, has received the National Cancer Institute (NCI) Outstanding Investigator Award, which encourages cancer research with breakthrough potential. Dr. Shaw, a member of Salk’s Molecular and Cell Biology Laboratory and holder of the...
Look for Opportunities to Lower Barriers to Participation of Older Patients in Oncology Clinical Trials
Practicing evidence-based medicine requires evidence, but the evidence for efficacy and safety of new and evolving cancer therapies in older adults is wanting due to their underrepresentation in oncology clinical trials. “It is difficult to practice evidence-based medicine in an older population...
‘Slow, Incremental Changes’ Are Increasing Participation of Older Adults in Clinical Trials
Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, FACP, FASCO, noted in an interview with The ASCO Post. Prompting those changes are...
Hospice and Palliative Medicine Fellowship Created at Fox Chase Cancer Center
The Pain & Palliative Care Program at Fox Chase Cancer Center is offering a new Hospice and Palliative Medicine fellowship in partnership with the Hospice of the Visiting Nurse Association of Greater Philadelphia and Temple University Hospital. The 1-year program is approved by the...
A Personal Tribute to Angela H. Brodie, PhD, a Scientist Who Transformed Breast Cancer Treatment
Angela H. Brodie, PhD, a pioneer in breast cancer research, passed away on June 7, 2017, from complications of Parkinson’s disease and pancreatic cancer. An obituary for Dr. Brodie was published previously in the June 25, 2017, issue of The ASCO Post. Here, Dr. Balkees Abderrahman shares a...
CheckMate-214: Nivolumab and Ipilimumab in Intermediate- and Poor-Risk Previously Untreated Advanced or Metastatic RCC
On August 15, Bristol-Myers Squibb Company announced topline results from the CheckMate-214 trial investigating nivolumab (Opdivo) in combination with ipilimumab (Yervoy) vs sunitinib (Sutent) in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell...
FDA Accepts sBLA and Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell Lymphoma
On August 16, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL). The sBLA and its acceptance is based on data from the phase III...
Recent FDA Actions Include New Drug Approvals in Leukemia, Expanded Approvals in Colorectal Cancer and Graft-vs-Host Disease
The U.S. Food and Drug Administration (FDA) recently granted approval, expanded approval, and breakthrough therapy designation to numerous treatments across a range of tumor types and malignancies. New Drug Approvals Daunorubicin-Cytarabine Combination (Vyxeos): On August 3, the FDA granted...
Robert L. Ferris, MD, PhD, Named Director of UPMC Hillman Cancer Center
Robert L. Ferris, MD, PhD, an expert in immunotherapy and a specialist in head and neck cancer, has been named Director of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center. His appointment was effective July 1. Dr. Ferris, a 15-year veteran of the UPMC Hillman Cancer...
Claire Verschraegen, MD, Joins OSUCCC–James
Claire Verschraegen, MD, has been appointed Director of the Division of Medical Oncology and Associate Director of the Translational Research Program at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....
Turmeric
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
Unraveling the Complexities of Cellular Immunotherapy and Its Potential to Cure Some Cancers
This past fall, the Fred Hutchinson Cancer Research Center in Seattle opened an all-encompassing 9,222-square foot outpatient cellular immunotherapy clinic, specifically designed to serve patients participating in the center’s novel immunotherapy clinical trials, which mainly focus on chimeric...
Triple-Negative Breast Cancer: Practical Approach, Promising Research
Triple-negative breast cancer has a reputation for being a particularly challenging malignancy, but breast cancer specialist Nancy Davidson, MD, Senior Vice President of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Seattle, put this in perspective in a recent...
ASCO Guideline on Stage IV NSCLC Therapy Updated
An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage IV non–small cell lung cancer (NSCLC) clarifies the role of immunotherapy in this setting. The update, published by Hanna et al in the Journal of Clinical Oncology, also provides new...
Short-Term Risk of Arterial Thromboembolism in Newly Diagnosed Patients With Cancer
Patients newly diagnosed with cancer may have a substantially increased short-term risk of arterial thromboembolism, according to a study published by Navi et al in the Journal of the American College of Cardiology. Patients with cancer face an increased risk of medical complications. However, the ...
Clonal Hematopoiesis in Patients With Nonhematologic Cancers
In a study of nearly 9,000 people treated for solid tumors, researchers found that radiation treatment and tobacco use were linked to higher rates of blood-based DNA mutations that could lead to a higher risk for blood cancers such as leukemia. The study, published by Coombs et al in...
Lung Cancer Clinical Trial Eligibility Criteria Increase in Number, Complexity
With the advent of molecular targeted therapies and immunotherapy, eligibility criteria have increased in number and complexity for lung cancer clinical trials, according to an analysis published by Garcia et al in the Journal of Thoracic Oncology. Despite calls to streamline cancer clinical trial...
Out-of-Pocket Costs Remain High, Even for Insured Patients With Cancer
One-third of insured people with cancer end up paying more out-of-pocket than they expected, despite having health insurance coverage, researchers at the Duke Cancer Institute have found. The data showed that costs such as copays and deductibles could lead to financial distress among insured...
Imaging and Biomarker Test Could More Accurately Predict Longer-Term Patient Response to Regorafenib in Colorectal Cancer
Administering a magnetic resonance imaging (MRI) scan and a blood test to patients with metastatic colorectal cancer may help to select those who would benefit from a targeted cancer treatment, a new study published by Khan et al in Gutreported. Researchers found that after only 2 weeks on the...
Increased Endometrial Cancer Rates Found in Women With Increased Levels of Cadmium
Through a 5-year observational study recently published by McElory et al in PLOS One, researchers at the University of Missouri (MU) found that women with increased levels of cadmium—a metal commonly found in foods such as kidney, liver, and shellfish, as well as tobacco—had an...
FDA to Expand Public Education Campaign to Focus on Prevention of Youth E-Cigarette Use
On August 8, the U.S. Food and Drug Administration (FDA) announced it would pursue a strategic, new public health education campaign aimed at discouraging the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) by children. The agency plans to expand its “The Real...
New Device to Test for Cervical Cancer May Be Less Painful for Patients, Produce Better Results
When a woman has an abnormal Papanicolaou (Pap) smear, she usually undergoes colposcopy—a procedure physicians use to closely examine the cervix, vagina, and vulva for signs of disease. Typically, a metal instrument is used to obtain a small sampling of cells inside the cervix, which is...
Identifying Essential Genes for Cancer Immunotherapy
A new study published by Patel et al in Nature identifies genes that are necessary in cancer cells for immunotherapy to work—addressing the problem of why some tumors don’t respond to immunotherapy, or respond initially but then stop as tumor cells develop resistance to...
Higher Opioid Use Among Cancer Survivors
A new study found that opioid prescription use is more common in cancer survivors than in individuals without a history of cancer. This was true even among survivors who were 10 or more years past their cancer diagnosis. Published by Sutradhar et al in Cancer, the findings come at a time of rising...
Senate Passes the RACE for Children Act
On August 3, the leadership of Kids v Cancer, an advocacy group promoting pediatric cancer research, issued the following statement: Today, the U.S. Senate passed the FDA Reauthorization Act and with it, the RACE for Children Act. Now, new cancer drugs will be developed not only for...
Perioperative Anti-inflammatory, Antistress Drugs May Reduce Postsurgical Metastatic Disease Recurrence
Most cancer-related deaths are the result of postsurgical metastatic recurrence. A new Tel Aviv University (TAU) study published by Shaashua et al in Clinical Cancer Research found a specific drug regimen administered prior to and after surgery significantly reduces the risk of postsurgical cancer...
Study Maps Mutation That May Drive Meningioma Development in Childhood Cancer Survivors
Neuroscientists may have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumor, decades after their treatment with cranial radiation. The findings, published by Agnihotri et al in Nature Communications, show that...
ASCO Resource to Help Your Patients Quit Tobacco
ASCO’s patient booklet Stopping Tobacco Use After a Cancer Diagnosis offers people with cancer and their caregivers information on why and how to quit tobacco use. With information on available treatments and resources, this booklet gives patients the practical tools to work with their health-care...
Don’t Miss Your Chance to Participate in the 2017 ASCO Practice Census
There is less than 1 month left to participate in this year’s ASCO Practice Census— the only annual survey of the entire U.S. oncology practice community that aims to identify changes in cancer care and oncology practice over time. It is crucial that practices in all settings across the United...
Practice Engagement Program Connects Practices to Resources to Adapt to Health-Care Changes
ASCO launched its Practice Engagement Program to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system. The Practice Engagement...
ASCO President Bruce E. Johnson Seeks to Bring Personalized Medicine, Real-Time Data to Every Oncology Practice
Dedicating one’s career and livelihood to the pursuit of treating and possibly curing cancer is, for many, a decision that stems from deeply personal and, often, tragic experience. For 2017–2018 ASCO President Bruce E. Johnson, MD, FASCO, the event that greatly influenced his decision was the...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
